Get the Stockscreener App
187.72
1.72%
3.18
After Hours:
187.72
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $187.72, with a volume of 1.73M.
It is up +1.72% in the last 24 hours and down -7.18% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$184.54
Open:
$183.36
24h Volume:
1.73M
Relative Volume:
0.85
Market Cap:
$291.13B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
56.38
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
+1.51%
1M Performance:
-7.18%
6M Performance:
+111.85%
1Y Performance:
+177.20%
1-Day Range:
$183.33
$187.78
1-Week Range:
$181.03
$187.78
52-Week Range:
$66.16
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
187.72 | 286.19B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,015.75 | 882.71B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.42 | 539.84B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
208.50 | 367.25B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
149.75 | 282.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca plc stock (GB0009895292): Jefferies maintains Buy rating - AD HOC NEWS
AstraZeneca to License Owkin AI Scientist for Development of Novel Biopharma Agents - Contract Pharma
AstraZeneca plc stock (GB0009895292): Global pharma leader with strong oncology pipeline - AD HOC NEWS
Owkin Expands AstraZeneca Collaboration Around K Pro AI Platform - Benzinga
AstraZeneca PLC stock (US6549022043): Full-year 2025 revenue surges 18% to $47.6B - AD HOC NEWS
ASTRAZENECA : Jefferies remains its Buy rating - marketscreener.com
AstraZeneca, Owkin to Develop AI Agents for Drug Discovery Decision-making - marketscreener.com
Astrazeneca Expands AI Partnership With Owkin Under Three-Year Licensing Deal - marketscreener.com
Is AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback? - Yahoo Finance
UAE approves AstraZeneca’s Baxfendy for hypertension - Pharmaceutical Technology
AstraZeneca (AZN) Reflects on Changes in FDA Leadership - GuruFocus
Sepsis Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
AstraZeneca Tracks Real-World Sinus Surgery Outcomes in China: What Investors Should Watch - TipRanks
AstraZeneca PLC stock (US6549022043): Global pharma leader in oncology and rare diseases - AD HOC NEWS
AstraZeneca's Phase 3 Trial Shows Significant Results in Patients With Hypoparathyroidism - marketscreener.com
AstraZeneca (AZN) Reports Positive CALYPSO Phase III Trial Resul - GuruFocus
AstraZeneca's Rare Disease Drug Shows Reduced Dependence On Calcium Supplements - Benzinga
AstraZeneca stock (GB0009895292): Q1 2026 earnings beat expectations with strong oncology growth - AD HOC NEWS
AstraZeneca stock trades down after FDA panel decision against camizestrant in breast cancer - Traders Union
AstraZeneca PLC (AZN) Stock Falls as FDA Panel Votes Against New Cancer Drug - Insider Monkey
AstraZeneca's Ongoing Vaccine Debate Amid Health Secretary's Que - GuruFocus
AstraZeneca stock (US6549022043): Q1 earnings beat fuels analyst upgrades - AD HOC NEWS
CDT Equity Advances AstraZeneca PLC (AZN)’s AZD5904 Into PCT Patent Protection Stage - Yahoo Finance
AZN Stock Quote Price and Forecast - CNN
AstraZeneca plc stock (GB0009895292): Beats Q1 Estimates, Analysts Raise Targets - AD HOC NEWS
AstraZeneca stock (US6549022043): Beats Q1 Estimates, Analysts Raise Targets - AD HOC NEWS
What next for AstraZeneca shares, after another cracking quarter? - MSN
AstraZeneca PLC stock (US6549022043): Strong 2025 results and pipeline momentum - AD HOC NEWS
AstraZeneca plc stock (GB0009895292): Pharma giant eyes growth amid pipeline progress and pricing pr - AD HOC NEWS
AstraZeneca prostate drug wins FDA panel backing as breast cancer candidate falters - MSN
AstraZeneca wins FDA AdCom backing for Truqap in prostate cancer - MSN
First City Capital Management, Inc.'s AstraZeneca PLC(AZN) Holding History - GuruFocus
FDA panel votes against AstraZeneca’s breast cancer drug - MSN
AstraZeneca (AZN) officer Sharma Mani granted additional Ordinary Shares - Stock Titan
Darren Sissons' Past Picks: AstraZeneca, Canadian Pacific Kansas City & Linde Plc - BNN Bloomberg
AstraZeneca plc Stock (GB0009895292): Strong Quarterly Results and Improved Outlook Support Shares - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): Strong quarterly results and improved guidance lift AZN shares - AD HOC NEWS
Fund Update: 25,553,763 ASTRAZENECA (AZN) shares added to Legal & General Group Plc portfolio - Quiver Quantitative
AstraZeneca Advances Respiratory And Oncology Portfolio Within FTSE 350 - Kalkine Media
AstraZeneca stock price forecast: GBX13,000 support holds as AZN edges lower - Traders Union
Astrazeneca (AZN) Stock Price, News & Analysis $AZN - MarketBeat
Alteogen posts weaker Q1 as Korea tech deals lag last year’s AstraZeneca windfallCHOSUNBIZ - Chosunbiz
AstraZeneca Reps Fight To Keep Opt-Ins In Pay Bias Suit - Law360
AstraZeneca slides Thursday, underperforms market - MarketWatch
AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026 - marketscreener.com
Jazz, AstraZeneca, Astellas: Foreign Healthcare's strongest Quant picks (JAZZ:NASDAQ) - Seeking Alpha
Eli Lilly To Invest $4.5 Billion More In Indiana Manufacturing SitesAstraZeneca (NYSE:AZN), Johnson & - Benzinga
AstraZenecaStatistics & Facts - Statista
AstraZeneca PLC (NYSE:AZN) Q1 2026 Earnings Call Transcript - Insider Monkey
Buying pressure lifts AstraZeneca stock higher in today's trading - Traders Union
AstraZeneca stock edges higher as revenue surpasses forecasts at $15.29 billion - Traders Union
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):